Pioglitazone does not increase cerebral glucose utilisation in a murine model of Alzheimer's disease and decreases it in wild-type mice

Diabetologia

Volumn 49, Issue 9, 2006, Pages 2153-2161

  Galea, E ^a   Feinstein, D L ^b   Lacombe, P ^c  

^a INSTITUT DE NEUROCIÈNCIES   (Spain)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c INSERM   (France)

Author keywords

Alzheimer's disease; Cerebral glucose utilisation; Murine model; Neurodegenerative diseases; Peroxisome proliferator activated receptor gamma; Transforming growth factor beta 1

Indexed keywords

CARBON 14; DEOXYGLUCOSE; GLUCOSE; PIOGLITAZONE; TRANSFORMING GROWTH FACTOR BETA1;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CONTROLLED STUDY; FEMALE; GLUCOSE UTILIZATION; IN VIVO STUDY; MALE; METABOLIC RATE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WAKEFULNESS;

ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANIMALS; BRAIN; CARBON RADIOISOTOPES; DEOXYGLUCOSE; DISEASE MODELS, ANIMAL; FEMALE; GLUCOSE; HETEROZYGOTE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33746662942     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-006-0326-0     Document Type: Article

References (42)

1. Hammarstedt A, Sopasakis VR, Gogg S, Jansson PA, Smith U (2005) Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia 48:96-104
2. Kubota N, Terauchi Y, Kubota T et al (2006) Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin dependent and independent pathway. J Biol Chem 281:8748-8755
3. Heneka MT, Klockgether T, Feinstein DL (2000) Peroxisome proliferator-activated receptor-γ ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 20:6862-6867
4. Cunard R, Eto Y, Muljadi JT, Glass CK, Kelly CJ, Ricote M (2004) Repression of IFN-gamma expression by peroxisome proliferator-activated receptor gamma. J Immunol 172:7530-7536
5. Schutz B, Reimann J, Dumitrescu-Ozimek L et al (2005) The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci 25:7805-7812
6. Feinstein DL (2004) Contrasting the neuroprotective and gliotoxic effects of PPARγ agonists. Drug Discov Today Ther Strategy 1:29-34
7. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC (2002) Protective action of the peroxisome proliferator activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. Neurochemistry 82:615-624
8. Lacombe P, Mathews PM, Schmidt SD et al (2004) Effect of antiinflammatory agents on transforming growth factor beta overexpressing mouse brains: a model revised. J Neuroinflammation 1:1-17
9. Dello-Russo C, Gavrilyuk V, Weinberg G et al (2003) Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 278:5828-5836
10. Brunmair B, Staniek K, Gras F et al (2004) Thiazolidinediones, like metformin, inhibit respiratory complex I. A common mechanism contributing to their anti-diabetic actions? Diabetes 53:1052-1059
11. Feinstein DL, Spagnolo A, Akar C et al (2005) Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol 70:177-188
12. Konrad D, Rudich A, Bilan PJ et al (2005) Troglitazone causes acute mitochondrial membrane depolarisation and an AMPK-mediated increase in glucose phosphorylation in muscle cells. Diabetologia 48:954-966
13. Petersen KF, Dufour S, Shulman GI (2005) Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents. PLoS Med 2:e233
14. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE (2005) Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 57:695-703
15. Sokoloff L (1981) Localization of functional activity in the central nervous system by measurement of glucose utilization with radioactive deoxyglucose. J Cereb Blood Flow Metab 1:7-36
16. El-Kebbi IM, Roser S, Pollet RJ (2004) Regulation of glucose transport by pioglitazone in cultured muscle cells. Metabolism 43:953-958
17. Shimaya A, Kurosaki E, Shioduka K, Nakano R, Shibasaki M, Shika H (1998) YM268 increases the glucose uptake, cell differentiation and mRNA expression of glucose transporter 3T3-L1 adipocytes. Horm Metab Res 30:543-548
18. Sorbi S, Bird ED, Blass JP (1983) Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann Neurol 13:72-78
19. de Leon MJ, Convit A, Wolf OT et al (2001) Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxyglucose/positron- emission tomography (FDC/PET). Proc Natl Acad Sci USA 98:10966-10971
20. Craft S, Zallen G, Baker LD (1992) Glucose and memory in mild senile dementia of the Alzheimer type. J Clin Exp Neuropsychol 14:253-267
21. Craft S, Asthana S, Cook DG et al (2003) Insulin dose-response effects on memory and plasmid amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 28:809-822
22. Watson GS, Craft S (2004) Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur J Pharmacol 490:97-113
23. Gibson GE, Sheu KF, Blass JP (1998) Abnormalities of mitochondrial enzymes in Alzheimer disease. J Neural Trans 105:855-870
24. Convit A, Wolf OT, Tarshish C, de Leon MJ (2003) Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci USA 100:2019-2022
25. Hoyer S (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer's disease. Eur J Pharmacol 490:115-125
26. Watson GS, Cholerton BA, Reger MA et al (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13:950-958
27. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Diabetes mellitus and risk of Alzheimer's disease and decline in cognitive function. Arch Neurol 61:661-666
28. Cukierman T, Gerstein HC, Williamson JD (2005) Cognitive decline and dementia in diabetes - systematic overview of prospective observational studies. Diabetologia 48:2460-2469
29. Wyss-Coray T, Lin C, Sanan DA, Mucke L, Masliah E (2000) Chronic overproduction of transforming growth factor-β1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. Am J Pathol 156:139-150
30. Wyss-Coray T, Lin C, Von Euw D, Masliah E, Mucke L, Lacombe P (2000) Alzheimer's disease-like cerebrovascular pathology in TGFβ1 transgenic mice and functional metabolic correlates. Ann NY Acad Sci 903:317-323
31. Gaertner RF, Wyss-Coray T, Von Euw D, Lesné S, Vivien D, Lacombe P (2005) Reduced brain tissue perfusion in TGFβ1 transgenic mice showing Alzheimer's disease-like cerebrovascular abnormalities. Neurobiol Dis 19:38-46
32. Tong XK, Nicolakakis N, Kocharyan A, Hamel E (2005) Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease. J Neurosci 25:11165-1174
33. Lautermäki R, Airaksinen KE, Seppanen M et al (2005) Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study. Diabetes 54:2787-2794
34. Magistretti PJ, Pellerin L (1996) Cellular bases of brain energy metabolism and their relevance to functional brain imaging: evidence for a prominent role of astrocytes. Cerebral Cortex 6:50-61
35. Carro E, Torres-Aleman I (2004) The role of insulin and insulin-like growth factor-I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 490:127-133
36. Steen E, Terry BM, Rivera EJ et al (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimers Dis 7:63-80
37. Smith D, Pernet A, Hallett WA, Bingham E, Marsden PK, Amiel SA (2003) Lactate: a preferred fuel for human brain metabolism in vivo. J Cereb Blood Flow Metab 23:658-664
38. Collino M, Aragno M, Mastrocola R et al (2006) Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/ reperfusion. Eur J Pharmacol 530:70-80
39. Lortz S, Gurgul-Convey E, Lenzen S, Tiedge M (2005) Importance of mitochondrial superoxide dismutase expression in insulin-producing cells for the toxicity of reactive oxygen species and proinflammatory cytokines. Diabetologia 48:1541-1548
40. Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB (2003) Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IkappaB alpha induction and block of NFkappaB and iNOS activation. J Neurochem 88:494-501
41. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE (2005) Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130:685-696
42. Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR (2006) Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol (Epub ahead of print) DOI 10.1016/j.expneurol.2006.01.018